Development of Adverse Outcome Pathways relevant for the identification of substances having endocrine disruptors properties-Reference-Cited by-同舟云学术

Development of Adverse Outcome Pathways relevant for the identification of substances having endocrine disruptors properties

Published:2023-02 Issue:2 Volume:20 Page:
ISSN:2397-8325
Container-title:EFSA Supporting Publications
language:
Short-container-title:EFSA Supporting Publications

Author:

Viviani Barbara¹,Bernardini Elena¹,Galbiati Valentina¹,Maddalon Ambra¹,Melzi Gloria¹,Midali Miriam¹,Serafini Melania¹,Corsini Emanuela¹,Melcangi Roberto Cosimo¹,Scanziani Eugenio²

Affiliation:

1. Dipartimento di Scienze Farmacologiche e Biomolecolari – DiSFeB Italy

2. Dipartimento di Medicina Veterinarie e Scienze animali‐ Via Dell'Università

Publisher

Wiley

Subject

General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.2903/sp.efsa.2023.EN-7748/fullpdf

Reference45 articles.

1. miR‐451: A Novel Biomarker and Potential Therapeutic Target for Cancer;Bai;Onco Targets Ther.,2019

2. Bansal N, Yendluri V, and Wenham RM, 2009. The Molecular Biology of Endometrial Cancers and the Implications for Pathogenesis, Classification, and Targeted Therapies. Cancer Control, Vol. 16, No. 1

3. Advances in chromatin remodeling and human disease;Cho;Current opinion in genetics & development,2004

4. Cancer epigenetics: from mechanism to therapy;Dawson;Cell.,2012

5. Endocrine‐disrupting chemicals: an Endocrine Society scientific statement;Diamanti‐Kandarakis;Endocrine reviews,2009

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing food safety risk assessment in China: development of new approach methodologies (NAMs);Frontiers in Toxicology;2023-11-17

2. Development of adverse outcome pathways relevant for the identification of substances having endocrine disruption properties Uterine adenocarcinoma as adverse outcome;EFSA Journal;2023-02